Highest-materiality recent filing
Halozyme Q1 revenue up 42% to $377M; new $1B buyback program
Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).
Halozyme full-year 2025 revenue $1.397B (up 38%), royalty record $868M; 2026 guidance reiterated
FY2025 total revenue $1.397B (+38% YoY); royalty revenue $868M (+52%) led by VYVGART Hytrulo, DARZALEX SC, Phesgo.
Halozyme raises 2026 guidance; acquires Surf Bio for $300M upfront
Preliminary 2025 revenue estimated at $1,385-1,400M (+36-38% YoY); royalties $865-870M (+51-52% YoY).
Halozyme awards CEO $10M performance-based RSUs tied to stock price targets $115-$170
Compensation Committee approved one-time PSU grant for CEO Dr. Helen Torley with $10M target fair value.
Halozyme issues $1.5B in convertible notes; repurchases $1.02B of existing notes
Issued $750M 0% convertible notes due 2031 and $750M 0.875% notes due 2032; net proceeds ~$1.47B.
Halozyme prices $1.3B convertible notes offering; to repurchase ~$1.02B of existing 2027/2028 notes
Priced $650M of 0% convertible notes due 2031 and $650M of 0.875% notes due 2032; initial purchasers have 13-day option for additional $200M.
Halozyme to offer $1.3B in convertible notes; extends credit facility to $750M
Amended credit facility: commitments increased to $750M, maturity extended to Nov 5, 2030; no outstanding borrowings.
Halozyme Q3 revenue up 22%, raises 2025 guidance, CFO transition announced
Q3 2025 revenue $354M (+22% YoY); royalty revenue $236M (+52% YoY); GAAP diluted EPS $1.43 (+36% YoY); non-GAAP diluted EPS $1.72 (+35% YoY).
Halozyme to acquire Elektrofi for $750M upfront plus up to $150M in milestones
Halozyme will pay $750M cash upfront for Elektrofi, subject to customary adjustments for debt, cash, expenses, and net working capital.
Halozyme to acquire Elektrofi for $750M upfront, expanding drug delivery offerings into 2040s
Upfront payment $750M; up to three $50M milestones contingent on product regulatory approvals.
Halozyme Q2 revenue $326M (+41% YoY); raises FY25 guidance, files patent suit vs Merck
Q2 total revenue $325.7M (+41% YoY); royalty revenue $205.6M (+65% YoY).
Halozyme Q1 revenue up 35% to $265M; raises FY25 guidance, announces $250M buyback
Q1 revenue $264.9M (+35% YoY); GAAP EPS $0.93 (+55%); non-GAAP EPS $1.11 (+41%).
Halozyme reports record 2024 revenue of $1.015B, Q4 net income up 60% YoY
Q4 total revenue $298M (+30% YoY); royalty revenue $170M (+40% YoY).
Halozyme raises 2025 guidance: rev $1.15-1.225B, adj EBITDA $755-805M, $250M ASR
Raises 2025 total revenue guidance to $1,150-$1,225M, representing 16-23% YoY growth from 2024 midpoint.
Halozyme Q3 revenue up 34% to $290M; raises full-year guidance on strong royalty growth
Total revenue $290.1M (+34% YoY); royalty revenue $155.1M (+36% YoY).
Halozyme beats Q2 with $231M revenue, $0.91 non-GAAP EPS; reiterates raised 2024 outlook
Revenue $231M (+5% YoY), net income $93M (+24%), GAAP EPS $0.72, non-GAAP EPS $0.91.
Halozyme Q1 revenue up 21% to $196M; non-GAAP EPS $0.79, net income $76.8M
Revenue $195.9M (+21% YoY), driven by 21% royalty growth to $120.6M from DARZALEX and Phesgo.
Halozyme Q4 revenue $230M (+27% YoY); reiterates 2024 guidance; $750M buyback
Q4 revenue $230M (+27% YoY); GAAP EPS $0.65, non-GAAP EPS $0.82; FY23 revenue $829M (+26%).
Halozyme prelim FY2023 revenue $827-832M; GAAP EPS $2.18-2.21
Revenue estimated $827-832M; royalties $445-450M for FY2023.
Halozyme Q3 royalty revenue up 15% to $114.4M; raises 2023 EBITDA & EPS guidance
GAAP diluted EPS $0.61, non-GAAP $0.75; royalty revenue $114.4M (+15% YoY).
Roche delays US launch of Tecentriq SC with Halozyme's ENHANZE to 2024
Roche informed Halozyme on Sept 6, 2023 of US launch delay for Tecentriq SC due to required CMC updates.
Halozyme Q2: revenue $221M, GAAP EPS $0.56, Non-GAAP $0.74; raises FY EPS guidance to $2.65-$2.75
Revenue $221.0M, +45% YoY; GAAP diluted EPS $0.56 vs $0.16 YoY; non-GAAP diluted EPS $0.74 vs $0.53.
Halozyme Q1 revenue up 38% to $162M; GAAP EPS $0.29; reiterates 2023 guidance
Revenue of $162.1M (+38% YoY); royalty revenue $99.6M (+43% YoY).
Halozyme says EPO revokes Janssen co-formulation patent; reaffirms 2023 guidance
EPO Opposition Division revoked Janssen's European Patent EP3370770B1 for DARZALEX SC co-formulation.
Halozyme discloses minimal SVB exposure; deposits insured, custodial accounts at separate banks
Cash deposit at SVB under $250,000 FDIC limit as of March 10, 2023.
Halozyme Q4 revenue up 78% to $181M; 2023 guidance $815-845M
Q4 revenue $181M (+78% YoY); full-year revenue $660.1M (+49% YoY).
Halozyme guides FY2023 revenue $815M-$845M, >20% growth; Non-GAAP EPS $2.50-$2.65
FY2023 total revenue guidance $815M-$845M, >20% growth over expected 2022 record revenue >$655M.
Halozyme Q3 revenue $209M (+80% YoY); GAAP EPS $0.44, non-GAAP $0.74
Royalty revenue $99.6M (+70% YoY) driven by DARZALEX SC and Phesgo.
Halozyme ups revolver to $575M, repays term loan and revolver with convertible note proceeds
Revolving credit facility increased by $225M to $575M; all other terms unchanged.
Halozyme issues $720M 1.00% convertible notes due 2028; repays term loan, buys back shares
Issued $720M in 1.00% Convertible Senior Notes due 2028, including $95M from over-allotment option.
Halozyme upsizes and prices $625M convertible notes due 2028, conversion premium ~30%
$625M aggregate principal; initial purchasers have option for additional $95M.
Halozyme proposes $500M convertible notes due 2028, plans $200M share repurchase and debt repayment
$500M aggregate principal of convertible senior notes due 2028; initial purchasers have option for additional $75M.
Halozyme completes Antares acquisition for $5.60/sh; total consideration ~$1.0457B
Aggregate purchase consideration $1,045.7M; each Antares share converted into $5.60 cash.
Halozyme Q2 revenue up 12% to $152.4M, raises FY22 revenue guidance to $655-685M
GAAP diluted EPS $0.16; non-GAAP diluted EPS $0.53. Royalty revenue $85.3M (+86% YoY).
Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.
On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.
On March 17, 2025, Michael J. LaBarre, Senior Vice President, Chief Technical Officer of Halozyme Therapeutics, Inc. (the “Company”) notified the Company of his decision to retire from the Company, effective March 17, 2025.
On February 11, 2025, Connie L. Matsui, a member of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”), notified the Company of her intention not to stand for reelection at the Company’s 2025 annual meeting of stockholders.
On February 22, 2023, James M. Daly, a member of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from the Company’s Board of Directors effective at the end of the 2023 calendar year.
On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc.
On March 11, 2022, Moni Miyashita was elected to the Board of Directors of Halozyme Therapeutics, Inc.
On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity.
On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately.
Effective January 3, 2022, Mark Snyder will be appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company.
Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to pursue another opportunity.
Max materiality 0.90 · Median 0.70 · Most common event earnings